KWD
MCID: KWS002
MIFTS: 72

Kawasaki Disease (KWD)

Categories: Bone diseases, Cardiovascular diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Kawasaki Disease

MalaCards integrated aliases for Kawasaki Disease:

Name: Kawasaki Disease 57 12 53 25 59 75 37 55 43 3 15 63
Mucocutaneous Lymph Node Syndrome 57 12 53 25 59 75 44 73
Kawasaki Disease, Susceptibility to 57 13 6 40
Kawasaki Syndrome 76 53 25 3
Acute Febrile Mucocutaneous Lymph Node Syndrome 12 25 29
Infantile Polyarteritis 57 75 73
Kd 57 25
Acute Febrile Mcls 12
Kawasaki's Disease 12
Mlns 12
Kwd 75

Characteristics:

Orphanet epidemiological data:

59
kawasaki disease
Inheritance: Multigenic/multifactorial; Age of onset: Adolescent,Adult,Childhood,Infancy; Age of death: normal life expectancy;

Classifications:



Summaries for Kawasaki Disease

OMIM : 57 Kawasaki disease is an acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy (Kawasaki, 1967). Coronary artery aneurysms develop in 15 to 25% of those left untreated (11,12:Kato et al., 1975, 1996), making Kawasaki disease the leading cause of acquired heart disease among children in developed countries. Treatment with intravenous immunoglobulin (IVIG) abrogates the inflammation in approximately 80% of affected individuals and reduces the aneurysm rate to less than 5%. Cardiac sequelae of the aneurysms include ischemic heart disease, myocardial infarction, and sudden death. Epidemiologic features such as seasonality and clustering of cases suggested an infectious trigger, although no pathogen had been isolated. Several lines of evidence suggested the importance of genetic factors in disease susceptibility and outcome. First, the incidence of Kawasaki disease is 10 to 20 times higher in Japan than in Western countries (Cook et al., 1989). Second, the risk of Kawasaki disease in sibs of affected children is 10 times higher than in the general population, and the incidence of Kawasaki disease in children born to parents with a history of Kawasaki disease is twice as high as that in the general population (Fujita et al., 1989; Uehara et al., 2003). Hata and Onouchi (2009) reviewed current knowledge on Kawasaki disease, including epidemiology, genomewide linkage analysis, and molecular genetics. (611775)

MalaCards based summary : Kawasaki Disease, also known as mucocutaneous lymph node syndrome, is related to vasculitis and rheumatic fever, and has symptoms including fever, edema of extremities and congestion of ocular conjunctivae. An important gene associated with Kawasaki Disease is ITPKC (Inositol-Trisphosphate 3-Kinase C), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Aspirin and Antipyretics have been mentioned in the context of this disorder. Affiliated tissues include lymph node, heart and tongue, and related phenotypes are ptosis and nausea and vomiting

Disease Ontology : 12 A lymphadenitis characterized by swelling of cervical lymph nodes in infants and young children and inflammation of medium-sized blood vessels located in body, has symptom fever, has symptom congestion of ocular conjunctivae, has symptom reddening of lips, has symptom reddening of oral cavity, has symptom protuberance of tongue papillae and has symptom edema of extremities.

Genetics Home Reference : 25 Kawasaki disease is a sudden and time-limited (acute) illness that affects infants and young children. Affected children develop a prolonged fever lasting several days, a skin rash, and swollen lymph nodes in the neck (cervical lymphadenopathy). They also develop redness in the whites of the eyes (conjunctivitis) and redness (erythema) of the lips, lining of the mouth (oral mucosa), tongue, palms of the hands, and soles of the feet.

NIH Rare Diseases : 53 Kawasaki disease is a disease that involves inflammation of the blood vessels. It is typically diagnosed in young children, but older children and adults can also develop this condition. Kawasaki disease begins with a fever that lasts at least five days. Other classic symptoms may include red eyes, lips, and mouth; rash; swollen and red hands and feet; and swollen lymph nodes. Sometimes the disease affects the coronary arteries which carry oxygen-rich blood to the heart, which can lead to serious heart problems. Kawasaki disease occurs most often in people of Asian and Pacific Island descent. The cause of Kawasaki disease is unknown. An infection along with genetic factors may be involved. Treatment includes intravenous gamma globulin and high doses of aspirin in a hospital setting.Prognosis is generally very good, but in cases of heart complications it depends on the severity of the coronary disease. 

MedlinePlus : 43 Kawasaki disease is a rare childhood disease. It makes the walls of the blood vessels in the body become inflamed. It can affect any type of blood vessel, including the arteries, veins, and capillaries. No one knows what causes Kawasaki disease. Symptoms include High fever that lasts longer than 5 days Swollen lymph nodes in the neck A rash on the mid-section and genital area Red, dry, cracked lips and a red, swollen tongue Red, swollen palms of the hands and soles of the feet Redness of the eyes Kawasaki disease can't be passed from one child to another. There is no single test. To diagnose it, doctors look at the signs and symptoms. They may also use an echocardiogram or other tests. It is mainly treated with medicines. Rarely, medical procedures and surgery also may be used for children whose coronary arteries are affected. Kawasaki disease can't be prevented. However, most children who develop the disease fully recover - usually within weeks of getting signs and symptoms. Further problems are rare. NIH: National Heart, Lung, and Blood Institute

CDC : 3 Kawasaki disease (KD), also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age. The disease was first described in Japan by Tomisaku Kawasaki in 1967, and the first cases outside of Japan were reported in Hawaii in 1976. Clinical signs include fever, rash, swelling of the hands and feet, irritation and redness of the whites of the eyes, swollen lymph glands in the neck, and irritation and inflammation of the mouth, lips, and throat.

UniProtKB/Swiss-Prot : 75 Kawasaki disease: An acute, self-limited vasculitis of infants and children characterized by prolonged fever unresponsive to antibiotics, polymorphous skin rash, erythema of the oral mucosa, lips, and tongue, erythema of the palms and soles, bilateral conjunctival injection, and cervical lymphadenopathy.

PubMed Health : 63 About kawasaki disease: Kawasaki (KAH-wah-SAH-ke) disease is a rare childhood disease. It's a form of a condition called vasculitis (vas-kyu-LI-tis). This condition involves inflammation of the blood vessels.In Kawasaki disease, the walls of the blood vessels throughout the body become inflamed. The disease can affect any type of blood vessel in the body, including the arteries, veins, and capillaries.Sometimes Kawasaki disease affects the coronary arteries, which carry oxygen-rich blood to the heart. As a result, some children who have Kawasaki disease may develop serious heart problems.

Wikipedia : 76 Kawasaki disease, also known as mucocutaneous lymph node syndrome, is a disease in which blood vessels... more...

Related Diseases for Kawasaki Disease

Diseases related to Kawasaki Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 553)
# Related Disease Score Top Affiliating Genes
1 vasculitis 32.1 CCL2 CRP ELANE SELE TNF
2 rheumatic fever 30.8 IL10 IL6 MBL2 TNF
3 myocarditis 30.8 IL6 NPPB TNF
4 coronary stenosis 30.7 ALB CRP IL6 NPPB
5 purpura 30.6 CRP IL6 TNF
6 toxic shock syndrome 30.5 IL10 IL6 TNF
7 arthritis 30.4 CCL2 IL10 IL6 MMP3 MMP9 TNF
8 cardiogenic shock 30.4 IL6 NPPB TNF
9 uveitis 30.3 CCL2 IL10 TNF
10 pericardial effusion 30.3 CRP IL6 NPPB
11 infective endocarditis 30.3 CRP FCGR2A IL6 TNF
12 colitis 30.3 IL10 IL6 S100A12 TNF
13 juvenile rheumatoid arthritis 30.3 CRP IL6 S100A12 TNF
14 endocarditis 30.2 ALB CRP FCGR2A HSPD1 IL10 IL6
15 acute cystitis 30.2 ALB CCL2 CRP IL6
16 graft-versus-host disease 30.2 IL10 IL6 TNF
17 hepatitis a 30.2 ALB IL10 TNF
18 cholangitis 30.1 ALB CRP IL6 TNF
19 psoriasis 30.1 CCL2 IL10 IL6 SELE TNF
20 drug reaction with eosinophilia and systemic symptoms 30.1 CRP TNF
21 capillary leak syndrome 30.1 ALB ELANE IL6
22 microscopic polyangiitis 30.1 IL10 TNF
23 contact dermatitis 30.1 IL10 IL6 SELE TNF
24 tuberculous meningitis 30.0 CCL2 MMP9 TNF
25 carotid stenosis 30.0 CRP MMP9 TNF
26 exanthem 30.0 CRP IL6 TNF
27 pertussis 30.0 IL10 IL6 TNF
28 polyarteritis nodosa 30.0 CRP IL6 SELE
29 myocardial infarction 29.9 ALB CCL2 CRP IL10 IL6 MMP3
30 heart disease 29.9 ALB CRP IL10 IL6 MMP3 NPPB
31 ischemic heart disease 29.9 CCL2 CRP IL6 NPPB TNF
32 angina pectoris 29.9 CRP IL6 NPPB
33 acute respiratory distress syndrome 29.8 ELANE IL6 TNF
34 inner ear disease 29.8 MMP9 TIMP1 TNF
35 myeloma, multiple 29.8 ALB CRP IL6 TNF
36 connective tissue disease 29.8 HSPD1 IL10 IL6 TNF
37 hemorrhagic fever 29.8 ALB IL10 IL6 TNF
38 acute pyelonephritis 29.8 ALB CRP IL10 IL6
39 mouth disease 29.8 CRP IL10 IL6 TNF
40 pre-eclampsia 29.8 IL10 IL6 SELE TNF
41 viral encephalitis 29.8 CCL2 IL10 IL6 TNF
42 acquired immunodeficiency syndrome 29.7 ALB IL10 IL6 TNF
43 dermatitis, atopic 29.7 CCL2 IL10 SELE TNF
44 adult respiratory distress syndrome 29.7 ELANE IL10 IL6 TNF
45 dengue hemorrhagic fever 29.7 ALB FCGR2A IL10 IL6 TNF
46 leptospirosis 29.7 CCL2 CRP IL10 IL6 TNF
47 toxoplasmosis 29.6 IL10 IL6 MYD88 TNF
48 aspergillosis 29.6 ELANE IL10 MBL2 TNF
49 synovitis 29.6 CRP IL6 MMP3 SELE TNF
50 meningitis 29.6 ALB CCL2 CRP FCGR2A IL10 IL6

Graphical network of the top 20 diseases related to Kawasaki Disease:



Diseases related to Kawasaki Disease

Symptoms & Phenotypes for Kawasaki Disease

Clinical features from OMIM:

611775

Symptoms:

12
  • fever
  • edema of extremities
  • congestion of ocular conjunctivae
  • reddening of lips
  • reddening of oral cavity
  • protuberance of tongue papillae

Human phenotypes related to Kawasaki Disease:

59 32 (show all 38)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ptosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000508
2 nausea and vomiting 59 32 occasional (7.5%) Occasional (29-5%) HP:0002017
3 arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001369
4 proteinuria 59 32 hallmark (90%) Very frequent (99-80%) HP:0000093
5 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
6 cranial nerve paralysis 59 32 occasional (7.5%) Occasional (29-5%) HP:0006824
7 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
8 arthralgia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002829
9 arrhythmia 59 32 occasional (7.5%) Occasional (29-5%) HP:0011675
10 hepatitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012115
11 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
12 edema 59 32 frequent (33%) Frequent (79-30%) HP:0000969
13 irritability 59 32 occasional (7.5%) Occasional (29-5%) HP:0000737
14 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
15 jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0000952
16 migraine 59 32 occasional (7.5%) Occasional (29-5%) HP:0002076
17 leukocytosis 59 32 frequent (33%) Frequent (79-30%) HP:0001974
18 cheilitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100825
19 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
20 erythema 59 32 hallmark (90%) Very frequent (99-80%) HP:0010783
21 pericarditis 59 32 frequent (33%) Frequent (79-30%) HP:0001701
22 myocarditis 59 32 occasional (7.5%) Occasional (29-5%) HP:0012819
23 recurrent pharyngitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100776
24 conjunctivitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000509
25 skin rash 59 32 hallmark (90%) Very frequent (99-80%) HP:0000988
26 meningitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001287
27 vasculitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002633
28 cholecystitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001082
29 lymphadenopathy 59 32 hallmark (90%) Very frequent (99-80%) HP:0002716
30 glossitis 59 32 frequent (33%) Frequent (79-30%) HP:0000206
31 interstitial pulmonary abnormality 59 32 occasional (7.5%) Occasional (29-5%) HP:0006530
32 abnormality of nail color 59 32 frequent (33%) Frequent (79-30%) HP:0100643
33 double outlet right ventricle with subpulmonary ventricular septal defect without pulmonary stenosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0011658
34 aseptic leukocyturia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100586
35 abnormality of the heart valves 59 Frequent (79-30%)
36 dilatation of the ascending aorta 59 Occasional (29-5%)
37 abnormal heart valve morphology 32 frequent (33%) HP:0001654
38 ascending tubular aorta aneurysm 32 occasional (7.5%) HP:0004970

UMLS symptoms related to Kawasaki Disease:


angina pectoris, edema, pruritus, chest pain, exanthema

GenomeRNAi Phenotypes related to Kawasaki Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 ALB CCL2 FCGR2A HSPD1 MYD88 S100A12

MGI Mouse Phenotypes related to Kawasaki Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 ELANE FCGR2A IL10 IL6 ITPKC MBL2
2 homeostasis/metabolism MP:0005376 9.93 ALB CRP ELANE IL10 IL6 MBL2
3 immune system MP:0005387 9.8 CCL2 CRP ELANE FCGR2A IL10 IL6
4 neoplasm MP:0002006 9.23 ALB ELANE IL10 IL6 MMP9 MYD88

Drugs & Therapeutics for Kawasaki Disease

PubMedHealth treatment related to Kawasaki Disease: 63

Medicines are the main treatment for Kawasaki disease. Rarely, children whose coronary (heart) arteries are affected may need medical procedures or surgery.The goals of treatment include:Reducing fever and inflammation to improve symptomsPreventing the disease from affecting the coronary arteries

Drugs for Kawasaki Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
2 Antipyretics Phase 4,Phase 2,Not Applicable
3 Analgesics, Non-Narcotic Phase 4,Phase 2,Not Applicable
4 Analgesics Phase 4,Phase 2,Not Applicable
5 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Fibrinolytic Agents Phase 4,Phase 2,Not Applicable
7 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Cyclooxygenase Inhibitors Phase 4,Phase 2,Not Applicable
13 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Platelet Aggregation Inhibitors Phase 4,Phase 2,Not Applicable
15 Immunoglobulin G Phase 4
16
Infliximab Approved Phase 3,Phase 2,Phase 1 170277-31-3
17
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
18
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
22 gamma-Globulins Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunoglobulins, Intravenous Phase 3,Phase 2,Phase 1,Not Applicable
24 Rho(D) Immune Globulin Phase 3,Phase 2,Phase 1,Not Applicable
25 Autonomic Agents Phase 3
26 Protective Agents Phase 3
27 Pharmaceutical Solutions Phase 3,Phase 2
28 alanine Phase 3
29 Dermatologic Agents Phase 3,Phase 2,Phase 1
30 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
32 Hormones Phase 3
33 Hormone Antagonists Phase 3
34 glucocorticoids Phase 3
35 Neuroprotective Agents Phase 3
36 Antiemetics Phase 3
37 Methylprednisolone acetate Phase 3
38 Prednisolone acetate Phase 3
39 Radiopharmaceuticals Phase 3,Phase 1,Phase 2
40 Technetium Tc 99m Sestamibi Phase 3,Phase 1,Phase 2
41 Antineoplastic Agents, Hormonal Phase 3
42
Pravastatin Approved Phase 2 81093-37-0 54687
43
Etanercept Approved, Investigational Phase 2 185243-69-0
44
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
45 tannic acid Approved Phase 2
46
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
47 Atorvastatin Calcium Phase 2,Phase 1 134523-03-8
48 Hypolipidemic Agents Phase 2,Phase 1
49 Calcium, Dietary Phase 2,Phase 1
50 Lipid Regulating Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease Completed NCT01524939 Phase 4 immunoglobulin G
2 Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial Completed NCT02298062 Phase 3 Infliximab;IVIG
3 Different Doses of IVIG for Kawasaki Disease Completed NCT02439996 Phase 3 IVIG (1g/kg,once);IVIG (1g/kg,twice);IVIG (2g/kg.once)
4 KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Recruiting NCT03065244 Phase 3 IVIG;Infliximab
5 A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Completed NCT00162032 Phase 3 Sestamibi
6 Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Completed NCT00760435 Phase 3 Infliximab;Placebo
7 Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease Completed NCT01596335 Phase 3 TA-650;Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
8 A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Recruiting NCT03200561 Phase 3 Prednisolone
9 Trial of Pulse Steroid Therapy in Kawasaki Disease--Pediatric Heart Network Completed NCT00132080 Phase 3 Steroids
10 Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders Completed NCT00157079 Phase 3
11 An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
12 Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
13 Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Unknown status NCT02114099 Phase 2 Atorvastatin
14 Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study Unknown status NCT02219165 Phase 2 Intravenous human immunoglobulin;Albumin
15 Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Completed NCT01431105 Phase 1, Phase 2 Atorvastatin
16 Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Recruiting NCT02179853 Phase 1, Phase 2 Anakinra
17 Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Withdrawn NCT02980263 Phase 2 Canakinumab
18 Anakinra and Kawasaki Disease Recruiting NCT02390596 Phase 2 Anakinra
19 Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Withdrawn NCT00305201 Phase 2 pravastatin
20 Etanercept in Kawasaki Disease Active, not recruiting NCT00841789 Phase 2 Etanercept;Placebo
21 Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease Recruiting NCT01917721 Phase 2 Doxycycline;Standard care
22 Prevention of Coronary Aneurysms in Kawasaki Syndrome Completed NCT00000520 Phase 2 immunoglobulins, intravenous;aspirin
23 A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Completed NCT00162045 Phase 1, Phase 2 Technetium Tc99m Sestamibi
24 Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Recruiting NCT03356769 Phase 2 Aspirin;AED;Placebo
25 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Completed NCT03174964 Phase 2 IVIg
26 Infliximab (Remicade) for Patients With Acute Kawasaki Disease Completed NCT00271570 Phase 1 Infliximab (Remicade)
27 Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease Unknown status NCT02359643 Not Applicable Aspirin
28 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
29 Etiology Study of Kawasaki Disease Unknown status NCT00154596
30 Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Unknown status NCT00861848
31 A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Recruiting NCT02951234 Not Applicable
32 Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Completed NCT02317913
33 Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease Completed NCT01440075 Not Applicable
34 Cardiovascular Status of Children 5 Years After Kawasaki Disease Not yet recruiting NCT03750123
35 Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. Recruiting NCT02771288 Not Applicable
36 Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States Completed NCT00875641
37 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
38 Reproductive Health in Men and Women With Vasculitis Completed NCT02176070
39 Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study Completed NCT01663129
40 A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Recruiting NCT02374450 Not Applicable

Search NIH Clinical Center for Kawasaki Disease

Cochrane evidence based reviews: mucocutaneous lymph node syndrome

Genetic Tests for Kawasaki Disease

Genetic tests related to Kawasaki Disease:

# Genetic test Affiliating Genes
1 Acute Febrile Mucocutaneous Lymph Node Syndrome 29 ITPKC

Anatomical Context for Kawasaki Disease

MalaCards organs/tissues related to Kawasaki Disease:

41
Lymph Node, Heart, Tongue, Eye, Skin, Endothelial, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Kawasaki Disease:

19
Body

Publications for Kawasaki Disease

Articles related to Kawasaki Disease:

(show top 50) (show all 2405)
# Title Authors Year
1
Giant right coronary artery aneurysm secondary to Kawasaki disease in an infant. ( 30337796 )
2019
2
Expression of tenascin C in cardiovascular lesions of Kawasaki disease. ( 30419479 )
2019
3
C-reactive protein and N-terminal pro-brain natriuretic peptide discrepancy: a differentiation of adenoviral pharyngoconjunctival fever from Kawasaki disease. ( 29441107 )
2018
4
Putting Out the Fire in Acute Kawasaki Disease. ( 29395176 )
2018
5
Acute myocarditis as a revealing clue of complete Kawasaki disease. ( 29976047 )
2018
6
Severe Late-Onset Kawasaki Disease Successfully Treated With Anakinra. ( 29912775 )
2018
7
Gastrointestinal involvement in Kawasaki disease: a case report. ( 29962358 )
2018
8
Epidemiological Differences in Kawasaki Disease Between Past and Recent Periods: The distribution dynamism and its implications. ( 29359523 )
2018
9
Utility of Coronary Computed Tomography Angiography in the Diagnosis and Management of Acute-Phase Adult-Onset Kawasaki Disease. ( 29899200 )
2018
10
Sudden Death as a Sequel of Ruptured Giant Coronary Artery Aneurysm in Kawasaki Disease. ( 29939842 )
2018
11
Kawasaki Disease - A Review of Treatment and Outcomes in an Irish Paediatric Cohort 2010-14. ( 29952440 )
2018
12
Arthritis in Kawasaki disease: A poorly recognised manifestation. ( 29943869 )
2018
13
Acute Rheumatic Fever, Kawasaki Disease or Alternative Diagnoses? A Call for the General Paediatrician. ( 29870101 )
2018
14
Predictors of intravenous immunoglobulin resistance and coronary artery aneurysm in patients with Kawasaki disease. ( 29768976 )
2018
15
The association between oxidative stress and endothelial dysfunction in early childhood patients with Kawasaki disease. ( 29426283 )
2018
16
Kawasaki Disease in the neonate: case report and literature review. ( 29970110 )
2018
17
Retrospective observational study indicates that the Pediatric Assessment Triangle may suggest the severity of Kawasaki disease. ( 29385646 )
2018
18
Kawasaki Disease. ( 29437127 )
2018
19
The relationship between Interleukin-27 gene polymorphisms and Kawasaki disease in a population of Chinese children. ( 29973303 )
2018
20
N-terminal pro-brain natriuretic peptide and prediction of coronary artery dilatation in hyperacute phase of Kawasaki disease. ( 29903669 )
2018
21
MicroRNA-145-5p and microRNA-320a encapsulated in endothelial microparticles contribute to the progression of vasculitis in acute Kawasaki Disease. ( 29343815 )
2018
22
Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial. ( 29933749 )
2018
23
miRa89186, a serum microRNA, induces endothelial cell apoptosis by targeting SMAD6 in Kawasaki disease. ( 29344637 )
2018
24
Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China. ( 29330741 )
2018
25
The association between the <i>miR-146a</i> rs2910164 C&amp;gt;G polymorphism and Kawasaki disease in a southern Chinese population. ( 29903729 )
2018
26
Unusual clinical sequalae of Kawasaki disease - symptomatic extracranial Internal carotid stenosis in young adult: A case report. ( 29920397 )
2018
27
Kawasaki Disease Shock Syndrome; A Unique and Severe Subtype of Kawasaki Disease. ( 29888440 )
2018
28
Macrophages and cytotoxic T cells infiltrate the destructed mitral tissue in Kawasaki disease. ( 29420247 )
2018
29
Dengue-Triggered Kawasaki Disease: A Report of 2 Cases. ( 29424760 )
2018
30
Environmental epidemiology of Kawasaki disease: Linking disease etiology, pathogenesis and global distribution. ( 29415012 )
2018
31
Atypical Kawasaki Disease Presenting with Hemiparesis and Aphasia: A Case Report. ( 29398757 )
2018
32
The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series. ( 29885546 )
2018
33
Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. ( 29948255 )
2018
34
Serum levels of C1q/tumor necrosis factor related protein-1 in children with Kawasaki disease. ( 29360808 )
2018
35
Myocarditis and Kawasaki disease. ( 29105303 )
2018
36
A case of Kawasaki disease masked by pustular type psoriasiform eruptions. ( 29892675 )
2018
37
<i>Clostridium difficile</i> colitis complicating Kawasaki disease in children: Two case reports. ( 29977558 )
2018
38
Capillary leak syndrome and aseptic meningitis in a patient with Kawasaki disease: A case report. ( 29879013 )
2018
39
ITPKC and SLC11A1 Gene Polymorphisms and Gene-Gene Interactions in Korean Patients with Kawasaki Disease. ( 29214786 )
2018
40
Differentiation between incomplete Kawasaki disease and secondary hemophagocytic lymphohistiocytosis following Kawasaki disease using N-terminal pro-brain natriuretic peptide. ( 29853942 )
2018
41
Acrodermatitis-Like Rash in Kawasaki Disease. ( 29628413 )
2018
42
Long-term outcome of coronary artery dilatation in Kawasaki disease. ( 29922008 )
2018
43
Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial. ( 29386515 )
2018
44
Innate immune responses following Kawasaki disease and toxic shock syndrome. ( 29447181 )
2018
45
Failure to Predict High-Risk Kawasaki Disease Patients in a Population-Based Study Cohort in Germany. ( 29406464 )
2018
46
Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. ( 29455693 )
2018
47
Cardiac function by Three Dimensional Speckle Tracking Imaging and Cytokines in Kawasaki Disease. ( 29350882 )
2018
48
Late and fatal onset of Kawasaki disease: Acute myocardial infarction complicated with cardiogenic shock as a late onset of Kawasaki disease. ( 30553629 )
2018
49
Kawasaki disease-related arthritis with synovial involvement. ( 30548392 )
2018
50
Incomplete Kawasaki Disease in an Infant with Cholangitis Post Kasai Surgery for Biliary Atresia. ( 29469036 )
2018

Variations for Kawasaki Disease

ClinVar genetic disease variations for Kawasaki Disease:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ITPKC NM_025194.2(ITPKC): c.1155+9G> C single nucleotide variant risk factor rs28493229 GRCh38 Chromosome 19, 40718299: 40718299
2 ITPKC NM_025194.2(ITPKC): c.1155+9G> C single nucleotide variant risk factor rs28493229 GRCh37 Chromosome 19, 41224204: 41224204

Expression for Kawasaki Disease

Search GEO for disease gene expression data for Kawasaki Disease.

Pathways for Kawasaki Disease

Pathways related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.01 CCL2 CRP ELANE FCGR2A IL10 IL6
2
Show member pathways
13.35 CCL2 IL10 IL6 MMP3 MMP9 MYD88
3
Show member pathways
13 CCL2 IL10 IL6 MBL2 MYD88 TNF
4
Show member pathways
12.58 CCL2 IL10 IL6 TIMP1 TNF
5
Show member pathways
12.32 ALB CCL2 CRP IL6 TNF
6
Show member pathways
12.31 CCL2 IL6 MMP3 MMP9 TNF
7
Show member pathways
12.25 FCGR2A IL10 MYD88 TNF
8 12.24 ELANE IL6 MMP3 MMP9
9 12.21 FCGR2A HSPD1 IL10 IL6 MYD88 TNF
10
Show member pathways
12.2 IL10 IL6 MYD88 TNF
11 12.17 HSPD1 IL10 IL6 TNF
12 12.09 CCL2 MMP9 SELE TNF
13 12.01 CCL2 FCGR2A IL6 MMP9 TNF
14 11.99 FCGR2A IL10 IL6 TNF
15
Show member pathways
11.98 FCGR2A HSPD1 IL6 MMP3 MMP9 TNF
16 11.91 CCL2 IL6 SELE TNF
17
Show member pathways
11.9 ELANE MMP3 MMP9 TIMP1 TNF
18 11.87 CCL2 IL6 MMP3 TNF
19 11.86 CCL2 MMP3 MMP9 TIMP1
20 11.84 CCL2 IL6 MMP3 MMP9 SELE TNF
21
Show member pathways
11.8 CRP IL6 TIMP1
22 11.76 CCL2 IL10 IL6 MMP3 MMP9 TIMP1
23 11.75 IL10 IL6 MYD88 TNF
24 11.73 IL10 IL6 TNF
25 11.65 CCL2 IL6 MMP9 TIMP1 TNF
26 11.64 MMP3 MMP9 TIMP1
27
Show member pathways
11.63 IL6 MMP3 MMP9 SELE TNF
28 11.6 HSPD1 IL6 MYD88 TNF
29 11.59 FCGR2A IL10 MBL2
30 11.53 ELANE IL6 MMP9 TNF
31 11.46 CCL2 IL10 IL6 TIMP1 TNF
32 11.42 ELANE MMP3 MMP9 SELE
33 11.36 IL10 IL6 TNF
34 11.34 CCL2 IL6 MMP9
35 11.26 IL10 IL6 TNF
36 11.2 CCL2 IL10 IL6 TNF
37 11.2 IL10 IL6 MYD88 SELE TNF
38 11.19 CCL2 MMP9 MYD88 TIMP1
39 11.12 CCL2 IL10 IL6 MYD88 SELE TNF
40 11.03 CRP IL6 TNF
41 11.02 CCL2 FCGR2A IL10 IL6 MMP3 MMP9
42 10.99 CCL2 IL10 IL6 TIMP1 TNF

GO Terms for Kawasaki Disease

Cellular components related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 ALB CCL2 CRP ELANE IL10 IL6
2 extracellular space GO:0005615 9.47 ALB CCL2 CRP ELANE HSPD1 IL10

Biological processes related to Kawasaki Disease according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.94 ELANE MMP9 SELE TNF
2 cellular response to lipopolysaccharide GO:0071222 9.91 CCL2 IL10 IL6 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 IL6 MYD88 S100A12 TNF
4 response to lipopolysaccharide GO:0032496 9.88 ELANE HSPD1 IL10 MYD88 SELE
5 positive regulation of inflammatory response GO:0050729 9.85 HSPD1 S100A12 TNF
6 regulation of inflammatory response GO:0050727 9.83 MYD88 SELE TNF
7 response to organic substance GO:0010033 9.83 HSPD1 IL10 TIMP1 TNF
8 positive regulation of MAP kinase activity GO:0043406 9.82 ELANE S100A12 TNF
9 response to glucocorticoid GO:0051384 9.81 HSPD1 IL10 IL6 TNF
10 humoral immune response GO:0006959 9.8 CCL2 IL6 TNF
11 defense response to bacterium GO:0042742 9.8 ELANE IL10 MBL2 MYD88 S100A12 TNF
12 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.78 IL10 MMP9 TNF
13 monocyte chemotaxis GO:0002548 9.77 CCL2 IL6 S100A12
14 extracellular matrix disassembly GO:0022617 9.76 ELANE MMP3 MMP9 TIMP1
15 inflammatory response GO:0006954 9.76 CCL2 CRP IL10 IL6 MYD88 S100A12
16 acute-phase response GO:0006953 9.75 CRP IL6 MBL2
17 lipopolysaccharide-mediated signaling pathway GO:0031663 9.74 CCL2 MYD88 TNF
18 positive regulation of interleukin-6 production GO:0032755 9.73 HSPD1 IL6 MYD88 TNF
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.71 ELANE IL6 MYD88 TNF
20 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.67 ELANE TNF
21 leukocyte migration involved in inflammatory response GO:0002523 9.67 ELANE SELE
22 opsonization GO:0008228 9.66 CRP MBL2
23 endothelial cell apoptotic process GO:0072577 9.65 IL10 TNF
24 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.65 IL10 TIMP1
25 positive regulation of chemokine biosynthetic process GO:0045080 9.65 MYD88 TNF
26 defense response to Gram-positive bacterium GO:0050830 9.65 CRP IL6 MBL2 MYD88 TNF
27 response to peptidoglycan GO:0032494 9.63 IL6 MYD88
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.62 IL10 TNF
29 positive regulation of neuroinflammatory response GO:0150078 9.62 IL6 TNF
30 regulation of neuroinflammatory response GO:0150077 9.6 MMP3 MMP9
31 negative regulation of chemokine biosynthetic process GO:0045079 9.56 ELANE IL6
32 cytokine-mediated signaling pathway GO:0019221 9.56 CCL2 IL10 IL6 MMP3 MMP9 MYD88
33 receptor biosynthetic process GO:0032800 9.55 IL10 TNF
34 negative regulation of lipid storage GO:0010888 9.54 CRP IL6 TNF
35 negative regulation of growth of symbiont in host GO:0044130 9.02 ELANE IL10 MBL2 MYD88 TNF
36 negative regulation of apoptotic process GO:0043066 10.04 ALB HSPD1 IL10 IL6 MMP9 MYD88
37 regulation of signaling receptor activity GO:0010469 10.01 CCL2 IL10 IL6 NPPB TIMP1 TNF

Molecular functions related to Kawasaki Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.56 ELANE MBL2 MMP3 MMP9
2 endopeptidase activity GO:0004175 9.5 ELANE MMP3 MMP9
3 protease binding GO:0002020 9.26 ELANE HSPD1 TIMP1 TNF
4 cytokine activity GO:0005125 9.02 CCL2 IL10 IL6 TIMP1 TNF
5 protein binding GO:0005515 10.09 ALB CCL2 CRP ELANE FCGR2A HSPD1

Sources for Kawasaki Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....